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A B S T R A C T
Hassallidins are cyclic glycolipopeptides produced by cyanobacteria and other prokaryotes. The hassallidin
structure consists of a peptide ring of eight amino acids where a fatty acid chain, additional amino acids, and
sugar moieties are attached. Hassallidins show antifungal activity against several opportunistic human patho-
genic fungi, but does not harbor antibacterial eﬀects. However, they have not been studied on mammalian cells,
and the mechanism of action is unknown. We puriﬁed hassallidin D from cultured cyanobacterium Anabaena sp.
UHCC 0258 and characterized its eﬀect on mammalian and fungal cells. Ultrastructural analysis showed that
hassallidin D disrupts cell membranes, causing a lytic/necrotic cell death with rapid presence of disintegrated
outer membrane, accompanied by internalization of small molecules such as propidium iodide into the cells.
Furthermore, artiﬁcial liposomal membrane assay showed that hassallidin D selectively targets sterol-containing
membranes. Finally, in silico membrane modeling allowed us to study the interaction between hassallidin D and
membranes in detail, and conﬁrm the role of cholesterol for hassallidin-insertion into the membrane. This study
demonstrates the mechanism of action of the natural compound hassallidin, and gives further insight into how
bioactive lipopeptide metabolites selectively target eukaryotic cell membranes.
1. Introduction
Cyanobacteria produce a large spectrum of bioactive natural pro-
ducts, such as antimicrobial, antifungal, antiviral, or cytotoxic com-
pounds [1–3]. Structurally diverse bioactive compounds from cyano-
bacteria are produced through ribosomal, nonribosomal, or hybrid
pathways and include compounds such as peptides, polyketides, ter-
penes, and lipopeptides. Novel compounds are constantly identiﬁed
through bioactivity-guided methods and genome mining. Despite the
vast number of natural products described from cyanobacteria, the
mechanisms of action of many bioactive compounds have been studied
less extensively. However, information on the target and the me-
chanism are ecologically important and essential if compounds will also
be evaluated for instance as pharmaceuticals or anti-fouling agents.
Lipopeptides are compounds with a fatty acid-derived moiety at-
tached to the amino-acid fragment. A number of cyanobacterial
bioactive compounds are lipopeptides with varying linear to cyclic
structures [1]. Anabaenolysins, calophycins, laxaphycins, lobocycla-
mides, lyngbyacyclamides, muscotoxins, and puwainaphycins are all
examples of cyclic lipopeptides extracted from cyanobacteria that ex-
hibit cytotoxic or antifungal activities [4–10]. In addition, antifungal
glycosylated cyclic lipopeptides known as hassallidins (A to E) are
produced by cyanobacteria [11–14]. The hassallidin structure consists
of a peptide ring of eight amino acids where one additional amino acid,
fatty acid, and one to three sugar moieties are attached. Hassallidins
have been found from cyanobacteria species Anabaena, Aphanizomenon,
Cylindrospermopsis, Nostoc, Planktothrix, and Tolypothrix [11,13,14].
Hassallidin family members known as balticidins were described from
Anabaena cylindrica [15]. Hassallidins have antifungal activities against
opportunistic human pathogenic fungi, including Candida, Aspergillus,
Fusarium, and Penicillium sp. [11–13,15,16]. Additionally, activity
against human acute T cell leukemia (Jurkat ATCC-TIB-152) and
murine aneuploid ﬁbrosarcoma (L929) cells has been reported [16].
Hassallidins are produced through a nonribosomal peptide biosynthesis
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pathway and the biosynthesis machinery was ﬁrst described in Ana-
baena sp. 90 [13,17]. In a comparison study between hassallidin A and
the structurally similar echinocandin antifungal caspofungin, the me-
chanism of action was hypothesized to involve the cell membrane [18].
Hassallidins are interesting molecules for research due to their
strong antifungal activity and complicated structure. Here we have
studied hassallidin D that was puriﬁed from the cyanobacterium
Anabaena sp. UHCC 0258. We tested its activity against eukaryotic cells,
including acute myeloid leukemia, normal rat kidney, and yeast cells.
The ultrastructural and cellular functions on mammalian cells were
studied to elucidate the mechanism of action. Furthermore, artiﬁcial
membranes together with in silico modeling were used to determine the
cellular target of hassallidin. This study presents the mechanism behind
the cytotoxic activity of hassallidins, namely disruption of membranes
containing sterols.
2. Materials and methods
2.1. Puriﬁcation of hassallidin D
A previously identiﬁed hassallidin producer cyanobacterium
Anabaena sp. UHCC 0258 (previously named as Anabaena sp. 258),
isolated from Lake Tuusulanjärvi, Finland, was maintained in 40ml
liquid Z8X culture medium [19]. For hassallidin D puriﬁcation, cells
were grown in batches of 3 l Z8X media for approximately 30 days at a
photo irradiance of 8 to 20 μmol m−2 s−1 at 20 to 25 °C. Cells were
collected by centrifugation for 10min at 7000×g and freeze dried. The
puriﬁcation of hassallidin was prepared following the previously pub-
lished procedure with some modiﬁcations [13]. In one batch, 2 g of
freeze-dried cyanobacterial biomass (1 g in two vials) were each dis-
solved in 35ml acetonitrile (ACN):dimethyl sulfoxide (DMSO) (1:1)
with a Silent Crusher M homogenizer (Heidolph, Germany) (30 s,
20000 rpm). The suspensions were centrifuged at 10000×g for 5min
and supernatants were pooled into a round bottom ﬂask. The pellets
were extracted again with 25ml ACN:DMSO (1:1) solution. Acetonitrile
was evaporated from the solution in a round bottom ﬂask with a rotary
evaporator at 30 °C. The extraction was continued as described [13] by
solid phase extraction (SPE) cartridges (Phenomenex Inc. Strata C18-E
5 g/20ml, 55 μm, 70 Å). Hassallidin D was further puriﬁed with a
semipreparative Luna C8 (2) 10× 150mm column with isocratic HPLC
(Agilent 1100) runs. HPLC was combined with a mass spectrometer
(LC/MSD trap XCT Plus, Agilent) to assess the correct peaks and the
purity of the analytes (Supplementary Fig. S1). The collected peaks
representing the four hassallidin variants were diluted in water (1:1)
and passed through SPE cartridges (Phenomenex Inc. Strata C18-E
200mg/6ml, 55 μm, 70 Å). Hassallidin was eluted from the cartridges
with 5ml 90% aqueous ACN. Fractions were dried with a stream of
nitrogen gas. The purity of hassallidin D was veriﬁed with QTOF
(Waters LC-MS: Acquity I-Class-Synapt G2-Si) (Supplementary Fig. S1).
Since some impurities were still found, we repeated the HPLC and SPE
puriﬁcation steps before freeze drying the isolated compounds. From a
total of 15 g of dried cyanobacterial biomass, approximately 11mg of
hassallidin D (2) was puriﬁed. The yield of variant 1 was about 2mg
and variants 3 and 4 were 1 to 1.5mg. Freeze-dried hassallidin D
variants were dissolved in DMSO to prepare 5-mM stock solutions for
use in experiments.
2.2. NMR analyses
NMR spectra of native hassallidin D (2) were recorded in DMSO‑d6
at 40 °C using a Bruker Avance III HD 850MHz NMR spectrometer
equipped with a 5-mm cryogenically cooled TCI probe head. 1H spectra
were acquired using 16,000 complex points, corresponding to an ac-
quisition time of 0.96 s and accumulated with 4 transients.
Homonuclear TOCSY and COSY spectra were accumulated with 8
transients, using 256 and 4096 complex points in F1 and F2
dimensions, corresponding to acquisition times of 15.1 ms and 241ms
in t1 and t2, respectively. The isotropic mixing time was 80ms for
TOCSY. Spectra of the heteronuclear multiple-bond correlation ex-
periment (13C-HMBC) was accumulated with 32 transients using 512
and 1536 complex points in F1 and F2, respectively. This translates to
acquisition times of 5.4 ms and 90ms in t1 and t2, respectively. A ﬁrst-
order J ﬁlter with 1JHC set to 140 Hz was used to remove one-bond
HeC connectivities, whereas 8 Hz for establishing multiple-bond HeC
correlations was used. A heteronuclear single quantum coherence ex-
periment (13C-HSQC) was acquired with 512 and 1024 complex points
in t1 and t2 domains, corresponding to acquisition times of 5.3 and
60ms, respectively.
Roughly 0.4 mg of hassallidin D (2) was hydrolyzed 1 h at 100 °C in
0.5 ml of 2M D2SO4 in D2O+DMSO‑d6 (9:1). Proton spectrum from
this and the reference compounds D-Mannosamine hydrochloride
(2mg, Sigma-Aldrich, St. Louis, USA) and D-(+)-Galactosamine hy-
drochloride (2mg, Sigma-Aldrich, St. Louis, USA) in the same solvent
system were run according to Giner et al. [20].
2.3. Monosaccharide MS analysis
D- and L-Mannose were purchased from Sigma-Aldrich (St. Louis,
USA). Hydrolysis of hassallidin D and sample derivatizations were done
according to Wang et al. [21] with the following exceptions: About
0.4 mg of hassallidin D was hydrolyzed, freeze dried instead of drying
under N2-gas stream, and the reagents L-cysteine methyl ester (Sigma)
and o-tolyl isothiocyanate (Thermo Fisher GmbH, Germany, instead of
phenyl isothiocyanate) were added simultaneously, and reaction mix-
ture was incubated at 60 °C for 1 h and diluted with MeOH before
UPLC-QTOF analysis. Samples of 1 μl were analyzed with two LC-
methods. The sample was injected to Kinetex C8 column (50 or
100× 2mm, 1.7 μm, Phenomenex Inc.), which was eluted
0.3 mlmin−1 at 40 °C with 95% water (+0.1% HCOOH, eluent A) and
5% ACN:isopropanol (1:1, +0.1% HCOOH, eluent B). Eluent B was
increased linearly to 100% in 5min, kept there 2min, then back to
initial condition in 0.5min with 2.5-min post run before next injection.
Additionally, the sample was eluted with Acquity UPLC® BEH C18
column (100× 2.1mm, 1.7 μm Waters Corp., MA, USA) as previously
but eluent B was increased linearly to 70% in 10min, then to 100% in
0.10min, kept there 3.99min, and changed back to initial condition in
0.5 min with 5.5-min post run. QTOF was used in resolution mode with
positive electrospray ionization. Leucine enkephalin was used as a lock
mass, sodium formate and Ultramark® 1621 for mass calibration. Re-
tention times of monosaccharide thiocarbamoyl-thiazolidine deriva-
tives were: D-Man 3.52min (D-Man 3.52, L-Man 4.22min), D-Ara
4.41min (D-Ara 4.89, L-Ara 4.91min), D-GlcNAc 3.48min (TR of D-
GlcNAc slightly preceding D-Man TR according to Tanaka et al. [22] or
with C18 column D-GLCNAc 3.95min (D-GlcNAc 3.94min, L-GlcNAc
not available).
2.4. Description of cell lines and general maintenance
MOLM-13 acute myeloid leukemia cells [23] were cultured in RPMI-
1640 medium (R5886, Sigma Life Science, UK) supplemented with 10%
(v/v) fetal calf serum (FCS, F7524 Sigma Life Science, UK), 8 mM L-
glutamine (Sigma Life Science, UK), and penicillin-streptomycin
(100 Uml−1 and 0.1mgml−1 respectively, Sigma Life Science, UK).
Normal rat kidney epithelial cells (NRK, ATCC CRL-6509) were cul-
tured in Dulbecco's Eagle's medium (DMEM, D6429, Sigma Life Science,
UK) with 10% FCS and penicillin-streptomycin solution. The cells were
maintained at 37 °C in 6% CO2. The cell lines were tested for myco-
plasma infection using MycoAlert™ (Lonza Rockland, Inc., USA) every
second month. No positive tests were obtained in any cell line during
the time of the experiments. Candida albicans was obtained as a frozen
culture (Department of Clinical Science, University of Bergen, Norway)
and grown on solid Sabouraud agar medium at 35 °C. A counting
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chamber and appropriate medium or sterile PBS (Sigma-Aldrich, St.
Louis, USA) were used to determine cell concentrations when preparing
working solutions.
2.5. Cytotoxicity assays
Hassallidin experiments were performed in 96-well culture plates
using 300,000 cells ml−1 (MOLM-13) or 70,000 cells ml−1 (NRK). NRK
cells were seeded in the wells the day before the experiments, whereas
MOLM-13 suspensions were prepared and seeded in the wells the day of
the experiments. Hassallidin D dilutions (prepared in PBS from the 5-
mM DMSO stock solutions) were added to the wells containing cells and
incubated for 24 h at 37 °C in 6% CO2. Assessment of cell death was
performed using the WST-1 proliferation assay (Roche, Mannheim,
Germany) following the manufacturer's instructions, and additionally
via microscopic evaluation of nuclear and surface morphology of the
cells after ﬁxation in 2% buﬀered formaldehyde containing
0.01mgml−1 of the DNA-speciﬁc ﬂuorescent dye Hoechst 33342
(Sigma-Aldrich, St. Louis, USA). EC50 values were estimated by non-
linear regression using the statistical software IBM SPSS statistics for
Apple (ver. 24, IBM Corp. Armonk, NY, USA):
= +
−
+ ( )
Y min max min( )
1 ICX
h50
(1)
where Y is the response (cell death), max and min, the maximum and
minimum cell death from the curve, X the concentration of the drug/
compound, and h is the hill index. This equation assumes that the EC50
point is equal to the inﬂection point, and that the concave and convex
part of the curve has equal geometry. This equation has proved to be a
reliable model for curve ﬁtting for cell death induction by various
toxins [24,25].
2.6. Transmission electron microscopy of MOLM-13 cells
MOLM-13 cells treated with hassallidin D (2) or solvent (for 5, 10,
or 15min with 5, 7.5, or 10 μM concentrations) were ﬁxed with 1.5%
glutaraldehyde in 0.1 M sodium cacodylate buﬀer. After a 2-h ﬁxation
at 4 °C, the samples were washed with sodium cacodylate buﬀer three
times. Samples were post-ﬁxed for 1 h with 1% osmium tetroxide in
0.1 M sodium cacodylate buﬀer and washed twice with sodium caco-
dylate buﬀer. Dehydration was prepared with increasing concentrations
of ethanol (30–100%) and ﬁnally propylene oxide (100%). Samples
were inﬁltrated and embedded into Agar-100 resin and hardened by
heating overnight at 60 °C. Ultrathin sections were prepared and im-
aged with a Jeol JEM-1230 transmission electron microscope at the
Molecular Imaging Center, Department of Biomedicine, University of
Bergen.
2.7. Flow cytometry
Flow cytometric analyses with propidium iodide (PI, Biolegend, San
Diego, USA) were performed with MOLM-13 (460,000 cells ml−1) or C.
albicans cells (500,000 cells ml−1 in PBS from overnight grown plate).
Samples treated with hassallidin D (2), digitonin (Merck, Darmstadt,
Germany) or solvents for 10min at 37 °C were transferred into
Eppendorf tubes and centrifuged at 100×g for 5min. After removing
250 μl of supernatant from samples, pellets were dissolved in 200 μl of
PBS. PI (0.2 μgml−1) was added into each sample 5min before mea-
surement. Samples were measured with an Accuri®C6 ﬂow cytometer
using 585/40 (FL2) bandpass ﬁlter. Flow cytometry was performed at
the Flow Cytometry Core Facility, Department of Clinical Science,
University of Bergen. Results were analyzed with FlowJo X program
(FlowJo LLC., version 10.3.0). EC50 values were estimated by non-
linear regression (see Eq. (1) in Section 2.5).
To assess cells for mitochondrial activity, MOLM-13 cells
(500,000 cells ml−1) treated with hassallidin D (2) or digitonin were
incubated for 10min at 37 °C in 6% CO2 and centrifuged at 160×g for
3min. The supernatants were removed and resuspended in 500 μl of
serum-free RPMI medium. After another centrifugation, 250 μl of
medium was replaced with an equal volume of 800 nM
Mitotracker®Red CM-H2XRos (M7513, Invitrogen™, Molecular Probes,
Inc., Eugene, OR, USA) in serum-free RPMI resulting in a ﬁnal con-
centration of 400 nM. The samples were incubated for 45min at 37 °C
in 6% CO2, washed with 900 μl of pre-warmed PBS, centrifuged at
163×g for 3min, and resuspended again in 450 μl PBS. SYTOX™ Blue
(S34857, Invitrogen™, Molecular Probes, Inc., Eugene, OR, USA) was
added to a ﬁnal concentration of 0.8 μM 5min prior to ﬂow cytometric
analyses. Samples were analyzed with a BD LSRFortessa™ ﬂow cyt-
ometer with bandpass ﬁlters 450/50 (407 violet) and 610/20 (561
yellow green) at the Flow Cytometry Core Facility, Department of
Clinical Science, University of Bergen. Results were analyzed with
FlowJo X program (FlowJo LLC., version 10.3.0).
2.8. Liposome preparations and assays
Liposomes were prepared by creating a phosphatidylcholine (PC)
lipid layer from 2.4 mgml−1 Emulmetik™ 930 (Lucas Meyer Cosmetics,
France) with or without 0.64mgml−1 cholesterol (Sigma, St. Louis,
USA) in CHCl3 by evaporation in a rotary evaporator. Calcein (Sigma,
St. Louis, USA) solution was prepared in a ﬁnal concentration of
100mM KCl and 10mM Tris buﬀered with NaOH. The pH of the calcein
solution was between 6.5 and 7.5. The lipid ﬁlms were hydrated in the
calcein solution at 70 °C and vortexed to create multi-lamellar vesicles
(MLV). Liposomes (large unilamellar vesicles) were created by ex-
truding the MLV solution through 0.4-μm and 0.2-μm ﬁlters (ﬁlter and
ﬁlter supports were Whatman® Nuclepore™ Track-Etched Membranes,
19mm, GE Healthcare, UK) using a syringe extruder (Avanti polar li-
pids, Alabaster, USA) at 65 to 70 °C. Extruded liposomes were then
passed through a Sephadex® size-exclusion column (G-50 medium, GE
Healthcare, UK) twice with KCl-Tris buﬀer (pH 7.0) to remove none-
ncapsulated calcein. The liposome sizes were measured by dynamic
light scattering (Malvern Zetasizer Nanoseries, Malvern, UK) and they
were on range of 164 to 182 nm.
To ﬁnd potential role of ergosterol on hassallidin membrane dis-
ruption, PC liposomes were produced using 2.4 mgml−1 L-a-phospha-
tidylcholine (Avanti Polar Lipids, Inc., Alabaster, USA) with or without
0.5 mgml−1 ergosterol (Sigma-Aldrich, St. Louis, USA) in CHCl3. A
43mM calcein solution (in 10% HEPES buﬀer with NaOH, pH adjusted
to 7.4) was used to rehydrate dried lipid ﬁlms by heating 70 °C and
vortexing. As before, formed MLV's were extruded, and ﬁltered then
through size-exclusion column with 10mM HEPES, 150mM NaCl so-
lution (pH 7.4). Liposome size measurements were carried out as de-
scribed above.
To study if changes in liposome concentrations had eﬀects on
membrane permeabilization ability of hassallidin, a set of PC liposomes
with cholesterol (2.4 mgml−1 L-a-phosphatidylcholine (95%, Avanti
Polar Lipids, Inc., Alabaster, USA; 0.65mgml−1 cholesterol, Sigma, St.
Louis, USA)) were prepared. These were prepared with the same calcein
and buﬀer solutions as the ergosterol liposomes.
The release of calcein from liposomes was continuously measured
with a ﬂuorescence spectrophotometer (Varian Cary Eclipse, excitation
495, emission 515, Agilent, USA) as described previously [26]. Lipo-
somes were diluted in KCl-Tris (100mM KCl, 10mM Tris) or HEPES-
NaCl buﬀer (10mM HEPES, 150mM NaCl, pH 7.4) to a total volume of
1ml. After 30 s recording to conﬁrm stable liposomes, hassallidin D (2)
or solvent was added. At 11min, 10% Triton-X was added to release all
remaining calcein.
2.9. In silico modeling of hassallidin-membrane interaction
Bilayers were constructed using the CHARMM membrane builder
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GUI [27] and converted to Lipid14 PDB format using the charmmlipi-
d2amber.x script [28]. The following two bilayers were constructed:
one system containing 128 POPC molecules and another system con-
taining 84 POPC and 44 cholesterol molecules, resulting in a molar
percentage of 35 for cholesterol in the second system. Both systems
used the TIP3P water model [29] and had 0.15M KCl salt concentration
added to the water layer. Hassallidin was included with identical
starting coordinates for both systems. All molecular dynamics simula-
tions were performed with the AMBER 16 software [30] using the GPU-
accelerated PMEMD implementation [31]. The full systems were energy
minimized and then heated from 0 to 100 K using Langevin dynamics
for 5 ps at constant volume with weak restraints on the lipid (force
constant of 10 kcal/mol/Å2). The volume was allowed to adjust as the
temperature increased to 300 K, keeping the weak restraint on the li-
pids. Production runs were then performed at constant pressure (1 atm)
regulated by the anisotropic Berendsen method [32] and temperature
(300 K) controlled by the Langevin thermostat [33]. Periodic boundary
conditions were applied where bonds involving hydrogen were con-
strained, allowing a 2-fs time step. Structural data was recorded every
10 ps for 300 ns.
3. Results
3.1. Isolation and identiﬁcation of four hassallidin D variants from
cyanobacterium Anabaena sp. UHCC 0258
The cyanobacterium Anabaena sp. UHCC 0258 produces diﬀerent
variants of hassallidin C and D [13] from which we aimed to purify
hassallidin D with aglyconic core of m/z 1283. Four variants of this
hassallidin D were puriﬁed that diﬀered in their amount of acetyl
groups (1–3 acetyl groups in diﬀerent positions thus yielding variants
1–4, Fig. 1). Hassallidin D (2) with two acetyl groups was the main
variant produced by this strain (see UV 280 nm trace in Supplementary
Fig. S1A). Hassallidin variants (1–4) were identiﬁed with HPLC-ITMS
and UPLC-QTOF. The behavior of the hassallidin D variants (1–4) in
HPLC-ITMS (Supplementary Fig. S1) was as reported before [13].
Comparison of the UPLC-QTOF ion mass diﬀerences of the four variants
to theoretical values resulted in−0.4 to 0 ppm verifying the elemental
composition of variants (Supplementary Fig. S1B). The structure of the
main hassallidin variant (2) was veriﬁed with MS and NMR (1H, 1H-1H
COSY, 1H-1H TOCSY, 1H-13C HSQC and 1H-13C HMBC, Supplementary
Fig. S2). In addition, the identity of monosaccharides, amino acid-
monosaccharide connections and locations of the mannose acetyl
groups were solved with MS and NMR (Supplementary Figs. S2–S5).
The two acetyl groups were situated in positions 4 and 6 in the mannose
unit (Supplementary Fig. S6). The annotated 1H-13C HMBC spectrum of
the carbonyl region illustrates the connections between amino acids
and between acetylated mannoses and acetyl groups (Supplementary
Figs. S6 and S7). Altogether, the data demonstrated that the main
hassallidin D (2) structure was 4,6-diacetylmannose-hassallidin D and
that this sample consisted of less than 1% remnants of other variants
(Supplementary Fig. S1C). The numerical NMR data (Supplementary
Table S1) are consistent with previously published hassallidin NMR
data [11–13].
3.2. Hassallidin D variants (1–4) induce cell death in both malignant and
normal mammalian cells
Many cyanobacterial compounds show promise as anti-cancer
agents [34–36]. We wanted to determine if hassallidins also possessed
such activity. However, all four puriﬁed hassallidin D variants (1–4)
were cytotoxic to both acute myeloid leukemia cells (MOLM-13) and
normal rat kidney cells (NRK) after 24-h incubation and with no se-
lectivity towards either of the cell types (Fig. 2A–D). In addition, freshly
isolated mouse hepatocytes were rapidly aﬀected when treated with
hassallidin for 2 h (data not shown). The main variant, hassallidin D
(2), was the most potent with a half-maximal eﬀective concentration
(EC50) of approximately 2.6 μM (Fig. 2B). The other three variants of
hassallidin (1, 3 and 4) had EC50 values between 3.5 and 5 μM (Fig. 2A,
C and D). It should be noted that the EC50 values of hassallidin 3 and 4
Fig. 1. Chemical structures of four hassallidin D variants (1–4) puriﬁed from cyanobacterium Anabaena sp. UHCC 0258.
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have a considerable degree of uncertainty due to the lack of data points
inducing cell death between 20 and 90% (Fig. 2C and D). Due to the low
yield of the other variants (1, 3 and 4) and the similar behavior in cell
assays, further tests were performed using only the main variant, has-
sallidin D (2). Additionally, the incubation time was reduced in further
tests, as the eﬀects of hassallidins were observed after less than one
hour (data not shown).
3.3. Ultrastructural analysis reveals membrane disruption caused by
hassallidin D
To study more speciﬁcally how hassallidin aﬀects eukaryotic cells,
we prepared transmission electron microscopy (TEM) slides from
MOLM-13 cells treated with hassallidin for 5 to 15min (Fig. 2E–L). The
ﬁrst signs of morphological changes were disappearance of microvilli
and smoothing of the cellular surface (Fig. 2F and J). At the same time,
the cytoplasm became less dense and the nucleus changed shape to
become more rounded with a smooth appearance. We next observed
that the cell surface membrane was broken or discontinuous with gaps
of several micrometers in length (Fig. 2K). Finally, the cell membrane
was completely disintegrated and the cytoplasm disappeared, leaving
only organelles and the nucleus (Fig. 2H and L). However, the mi-
tochondria were easily distinguishable throughout the cell death pro-
cess (Fig. 2J, K, L) and appeared unharmed even when the remainder of
the cell had disintegrated (Fig. 2L).
3.4. Hassallidin D induces rapid lysis of eukaryotic cell membrane allowing
internalization of small molecules
The cytotoxic eﬀects of hassallidin on cell viability were conﬁrmed
with propidium iodide (PI) staining of MOLM-13 cells. This method
detects loss of cell surface membrane integrity by measuring increased
PI internalization [37]. Increasing hassallidin concentrations resulted in
a higher number of PI-positive cells (Fig. 3), which is consistent with
the ultrastructural ﬁndings (Fig. 2E–L). There was a marked increase in
PI internalization at 2.5 μM hassallidin and almost all cells were PI
positive at 5 μM (Fig. 3A). The EC50 for hassallidin-induced PI inter-
nalization was 4.8 μM after a 15-min incubation (Fig. 3B). We com-
pared the eﬀect with that of the biodetergent digitonin [26,38,39].
While both digitonin and hassallidin seemed to aﬀect the cells similarly,
digitonin was slightly less potent with an EC50 of 6.5 μM (Fig. 3B). Since
hassallidin has shown antifungal activities [11–14,16], we examined if
membrane disruption also occurred in Candida albicans treated with
hassallidin and compared again with digitonin (Fig. 3C and D). A sig-
niﬁcantly higher concentration of hassallidin or digitonin was required
to cause PI internalization into yeast cells after a 15-min incubation
(Fig. 3C and D). The EC50 for C. albicans was approximately 30 μM for
both hassallidin and digitonin (Fig. 3D).
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Fig. 2. Hassallidin D induces rapid ruptures in mammalian cell membranes leading to cell death. (A–D) Four hassallidin D variants (1–4) exhibit similar eﬀects
against two diﬀerent mammalian cell lines, MOLM-13 and NRK. Results were obtained after a 24-h incubation by ﬂuorescent microscopy counting. Data are shown as
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3.5. Hassallidin D distinguishes between mitochondrial and cell surface
membranes
Although hassallidin D caused membrane disruption inevitably
leading to cell death, TEM images indicated that not all cellular con-
stituents were aﬀected equally (Fig. 2H and L). To determine if the
mitochondria were functional after membrane disintegration, we
double-stained MOLM-13 cells with SYTOX™ Blue for membrane in-
tegrity and Mitotracker®Red CM-H2XRos to detect viable mitochondria
(see Supplementary Fig. S9 for details on gating strategy). Similar to PI
(Fig. 3), we observed an increase in SYTOX™ Blue-positive cells with
increasing hassallidin or digitonin concentrations (Fig. 4). However, the
decline in mitochondrial function did not follow the decline in cell
surface membrane integrity (Fig. 4D and H). Functional mitochondria
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were observed even at 5 μM hassallidin, a concentration at which al-
most all cells were broken or dead (Fig. 4C). The observed diﬀerence
between mitochondria and cell surface membrane disruption was si-
milar for both hassallidin (Fig. 4A–C) and digitonin (Fig. 4E–G).
3.6. Hassallidin D shows cholesterol-dependent membrane disruption on
artiﬁcial membranes and in silico
One of the main diﬀerences between mitochondrial and cell surface
membranes is cholesterol content. Mitochondria have signiﬁcantly
lower amounts of sterols in their membranes [40]. To determine if the
presence of cholesterol was the limiting factor for hassallidin activity,
we studied the eﬀects of hassallidin on cell membranes by constructing
liposomes with membranes of pure phospholipids or of phospholipids
and cholesterol. Addition of hassallidin into the suspension of choles-
terol-containing liposomes caused an immediate release of calcein from
the liposomes, which was seen as a rapid increase of ﬂuorescence in-
tensity (Fig. 5A). At 0.8 μM concentration, hassallidin caused almost
complete release of calcein from the liposomes within 1min. A reduc-
tion to 0.4 μM hassallidin caused signiﬁcant calcein release, which did
not stabilize during the time of the experiment (11min), indicating that
the liposomal membrane was permanently disrupted. We did not detect
any calcein release from the liposomes at 0.3 μM hassallidin, suggesting
that the membrane was intact. In contrast, the liposomes without
cholesterol in their membrane exhibited only modest calcein release
even after treatment with 30 μM hassallidin (Fig. 5B), corresponding to
the amount observed with 0.4 μM hassallidin in the cholesterol-con-
taining liposomes (Fig. 5A). Moreover, we observed an initial leakage,
which stopped since the curve appeared to ﬂatten (Fig. 5B, black line).
Hassallidin thus showed speciﬁc membrane-disrupting activity against
cholesterol-containing membranes (Fig. 5). The fungal membranes
contain ergosterol instead of cholesterol. To reveal if either of these
sterols were necessary for hassallidin-induced permeabilization, we
produced liposomes with ergosterol instead of cholesterol. Ergosterol
liposomes were also highly sensitive to hassallidin (Fig. 5C). The ap-
parent decrease in signal over time seen in Fig. 5C and D could be at-
tributed to fading of the ﬂuorophore by the UV spectrophotometer, or
by quenching of the released calcein. The hassallidin concentration
required for the disruption of ergosterol liposomes was slightly higher
than for cholesterol liposomes, which could be attributed to a diﬀerent
batch of PC from a diﬀerent supplier (see the Materials and methods
Section 2.8 for details). By repeating leakage assay with diﬀerent con-
centrations of cholesterol liposomes, a logical trend was observed that
more hassallidin is needed to produce the same eﬀect in higher amount
of liposomes (Supplementary Fig. S10).
We further studied the eﬀects of hassallidin on lipid membranes by
in silico simulations of hassallidin in complex with 1-palmitoyl-2-oleoyl-
sn-glycero-3-phosphatidylcholine (POPC) bilayers with or without
embedded cholesterol (Fig. 6, Supplementary Videos S1 and S2). The in
silico modeling supported the ﬁnding of cholesterol dependency
(Fig. 5A) in that hassallidin acyl chain inserted into the bilayer when
cholesterol was present (Fig. 6A, C, E). Hassallidin only slightly inter-
acted with the surface of the phosphatidylcholine bilayer (without in-
sertion) when cholesterol was not present (Fig. 6B, D, F). There was
rapid insertion of the fatty acid into the membrane with cholesterol
(Fig. 6C) accompanied by association of the tyrosine-5 ring into the
polar part of the lipid membrane (Fig. 6E). Calculated order parameters
together with visual inspection of the bilayer trajectories showed that
cholesterol induces an ordering of the POPC fatty acids together with a
straightening of the aliphatic chains (Fig. 6G and H). Cholesterol thus
increases the distance between phosphate groups of each leaﬂet in the
bilayer from slightly below to slightly above 40 Å (Fig. 6C-F, red
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traces).
4. Discussion
The cyclic glycolipopeptide hassallidins are mostly known from
their antifungal activities and their wide distribution among cyano-
bacteria [11–14,16]. However, their mechanism of action has remained
unclear. In this study, puriﬁed hassallidin D variants from cyano-
bacterium Anabaena sp. UHCC 0258 were shown to have general
toxicity on mammalian cells, including normal and malignant cells.
Furthermore, hassallidin D (2) induced permeabilization of the surface
membrane but left mitochondria viable. Experiments on isolated
membrane systems revealed that hassallidin D (2) preferentially dis-
rupts sterol-containing membranes.
The four puriﬁed hassallidin D variants (1–4) showed cytotoxic ef-
fects against eukaryotic cells (Fig. 2). Ultrastructural analysis
(Fig. 2C–L) together with PI internalization (Fig. 3) demonstrated that
hassallidin D (2) rapidly disrupted cell membranes. The lack of mi-
tochondrial lysis (Fig. 2J–L), and the fact that mitochondria were
functional after surface membrane disruption (Fig. 4) is in line with
their low sterol content, reported to be about 10 times lower than in
eukaryotic surface membranes [40,41]. Among the many cytotoxic
compounds described from cyanobacteria, there are only few com-
pounds that have shown similar membrane lytic eﬀects. Anabaenoly-
sins isolated from Anabaena sp. and muscotoxins from Desmonostoc
muscorum have shown similar results in cellular and liposomal assays
[8,26]. However, muscotoxins permeabilize liposomes without choles-
terol [8]. Thus, the eﬀects of anabaenolysin and hassallidin seem to be
analogous and even the EC50 values for cytotoxicity of hassallidin and
anabaenolysin are similar [26].
Similar to the anabaenolysins, our results indicated that the eﬀects
of hassallidin may resemble surface-active compounds such as the sa-
ponin digitonin. Digitonin is known to speciﬁcally interact with cho-
lesterol in membranes, which then causes changes in cell surface
membrane curvature [38,39]. Hassallidin D (2) was also dependent on
cholesterol as it speciﬁcally disrupted artiﬁcial liposomes prepared with
cholesterol and phosphatidylcholine (Fig. 5). These observations are
similar to those of digitonin in liposomal assay [26]. In addition to
digitonin and anabaenolysin, there are other natural products that
permeabilize membranes and associate with sterols, such as theo-
nellamide A [42] and iturins [43–45].
While hassallidins are structurally diﬀerent from the other mem-
brane-active molecules mentioned above, it shares the presence of a
fatty acid moiety. In silico modeling revealed that the ﬁrst contact
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between hassallidin and the membrane was through the amino acids of
the hassallidin, and the lipid tail of hassallidin inserted into the cho-
lesterol-containing membrane immediately after (Fig. 6A and Supple-
mentary Video S1). Interestingly, hassallidin seemed to enter deeper
into the membrane during the course of the in silico modeling (Fig. 6C
and E and Supplementary Video S1). The conformation of hassallidin
remained quite stable during invasion into the cholesterol-containing
membrane when compared with membranes without cholesterol. The
lipid tail insertion into the membrane alone is not expected to break the
membrane. However, the large polar head of the hassallidin molecule
generates a very conical geometry. When the hassallidin has inserted
into the membrane, it may change the membrane curvature to become
more convex, and the membrane structure is eventually disrupted, as
has been described for surfactin [46]. If this was the case, one could
expect that there must be a minimal ratio of hassallidin molecules per
area of lipid membrane. This can be found by investigating whether the
concentration of lipids inﬂuences the eﬃcacy of hassallidin (e.g. the
concentration needed to obtain 50% release of calcein). We found that
higher lipid concentrations needed higher hassallidin concentration to
obtain the same eﬀect (Supplementary Fig. S10), showing that hassal-
lidin-induced membrane disruption is not a local eﬀect, but rather de-
pendent on a certain partitioning between hassallidin and lipids [47].
In our model of one hassallidin molecule, hassallidin did not seem to
interact directly with cholesterol such as observed for digitonin
[38,39], suggesting that cholesterol may simply provide a better or-
ganized and structured membrane, which enables hassallidin insertion.
The thickening of the bilayer (Fig. 6C–E, red lines) and ordering of the
fatty acids observed (Fig. 6G and H) are in agreement with previous
studies on membranes with increasing cholesterol content as shown
both experimentally and in simulations [48,49]. Although the simula-
tion does not cover the timeframe needed to reach steady state condi-
tions for hassallidin insertion into membrane, it still ﬁts with the data
obtained with liposomes (Fig. 5). We would expect some interaction
with non-cholesterol membranes at higher hassallidin to lipid ratio and
simulation run at longer time-frames, in line with what was observed in
Fig. 5B. Also, due to the limited number of molecules, our model is not
able to provide an exact molecular explanation for the disruption of the
bilayer integrity. To obtain this, a much larger model with several
hassallidin molecules must be made on a longer time-scale, which is not
possible with our all-atom model. Membrane-permeabilization com-
pounds may have a speciﬁc attachment route, such as digitonin with
cholesterol [38,39]. Some compounds are known to create a channel
through the membrane by creating a complex of several molecules [50],
while some compounds may have more than one mode of action. For
example, amphotericin B has been found to bind directly to ergosterol
in addition to its channel-formation activities [51]. However, the target
of hassallidins is clearly the cell surface membrane; this was already
hypothesized in the study where the eﬀects of hassallidin A against C.
albicans were compared to those of the echinocandin antifungal cas-
pofungin due to their structural similarities [18], and conﬁrmed here.
It has been shown that the activity of hassallidin is diminished by
the opening of the ring structure [13]. This demonstrates that there are
elements in the ring structure that are essential for obtaining a close
association with the membrane and to direct the fatty acid moiety to-
wards the inner core of the membrane bilayer (for example, compare
Fig. 6A and C with Fig. 6B and D). From in silico modeling, we observed
that hassallidin associates several times with the membrane without
cholesterol, but then dissociates rapidly. After the ﬁrst contact between
hassallidin and the cholesterol-containing membrane, the tyrosine-5 is
located close to the membrane, eventually being located inside the
outer phosphate atoms of the phospholipids (Fig. 6E). Since the linear
variant of hassallidin is less potent [13], the spatial relationship be-
tween the fatty acid and the aromatic amino acids appears to be im-
portant to induce membrane insertion and eventually lysis.
Hassallidin variants A to E and balticidins are found from a large
variety of cyanobacteria [11–15,52], and there are also other
prokaryote compounds that structurally belong to the hassallidin family
and have similar antifungal activity. Thus, hassallidins and balticidins
from cyanobacteria, herbicolins from Erwinia herbicola [53], jagaricin
from Janthinobacterium agaricidamnosum [54], chromobactomycin from
Chromobacterium sp. C61 [55], and Sch 20561 and Sch 20562 from
Aeromonas sp. W-10 [56,57] all share a similar glycopeptide structure
attached to a lipid tail with varying lengths. These molecules do not
possess antibacterial activities with the exception of the anti-
mycobacterial activities of herbicolin A [58]. The sterol dependency of
hassallidin D could explain the absence of antibacterial activity, as
bacterial membranes generally do not contain sterols (see [59] for a
review on sterols in microorganisms). The eﬀects of these molecules
against mammalian cells have been reported only for a few cell lines
[16]. We directly compared the eﬀects of hassallidin D on human and
yeast cells and observed that both hassallidin and digitonin were more
potent against human cell lines compared than against C. albicans
(Fig. 3). This could be explained by the presence of a cell wall in yeast,
which makes the surface membrane less accessible to the toxins. Has-
sallidins are still eﬀective compounds against a range of opportunistic
fungi. The EC50 for PI internalization into C. albicans was approximately
30 μM (Fig. 3D), which is higher than reported MIC values (MIC
1.5–16 μM, IC50 0.3–1 μM) [11–13,16]. The discrepancy between our
ﬁndings on PI internalization and previous MIC data can be explained
by the diﬀerence in assay. Whereas PI internalization reports membrane
intactness during a few minutes, and is not a measure of viability, MIC
gives an indication of the proliferation rate of the culture over longer
time period. The latter could be inﬂuenced by mechanisms that are not
detectable in a membrane intactness assay like ours. In conclusion,
hassallidins seem to have general toxicity against eukaryotic cells,
which all have sterols in their membranes. Accordingly, hassallidins are
unlikely candidates for antifungal drugs.
The ecological rationale for producing hassallidin or related com-
pounds is still unknown. Nevertheless, many diﬀerent bacterial species
produce these compounds and the geographical range of habitats is
constantly increasing [13,60]. This suggests that these compounds
provide an evolutionary beneﬁt. The ecological interactions of the mi-
crobial compounds may be very complicated. It was recently shown
that the antifungal eﬀect of anabaenolysin was enhanced by cyclo-
dextrins, which were also produced by the same cyanobacteria [61].
The biodetergent digitonin has also been found to enhance drug eﬀects
[62,63]. Further research could be focused on the interactions of has-
sallidin with other compounds or if hassallidins already have a natural
co-eﬀector compound.
5. Conclusions
Microbial natural products participate in complex ecological webs
by acting as for instance defense or signal molecules. Many of these
products are also valuable to humans as pharmaceuticals or in bio-
technological applications. Through the identiﬁcation and observation
of natural products, their ecological role can be understood and their
potential for other applications can be evaluated. Here, we studied the
antifungal and cytotoxic cyclic glycolipopeptide hassallidin D. We de-
termined the mechanism of action for hassallidin D puriﬁed from cya-
nobacterium Anabaena sp. UHCC 0258. We observed that hassallidin D
speciﬁcally disrupts sterol-containing cell surface membranes. Many
cyanobacteria strains have been identiﬁed as hassallidin producers
from diﬀerent habitats and other microbes produce hassallidin family
compounds as well, which indicates that membrane-eﬀective com-
pounds play an important ecological role.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.bbamem.2019.03.010.
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